Impact of Precision Medicine on Oncology Field

Precision medicine is changing how physicians think about treatments, with great advances coming out of the oncology field.  In podcast No. 42, three CHOC experts and speakers at the upcoming Peds2040 conference, Dr. Anthony Chang, Dr. Leonard Sender and Spyro Mousses, Ph.D., discuss exciting developments impacting patients today and offering tremendous hope for the future.

Dr. Sender, medical director of the Hyundai Cancer Institute at CHOC, is determined to find a cure for cancer and prevent or reduce the toxicity associated with treatments.  Under his leadership, CHOC has programs in place that bring together big data, bioinformatics and genomic sequencing.  In addition to discussing what CHOC is currently doing, he and Dr. Mousses, whose interested include artificial intelligence, share plans for the near future, including offering very complex molecular profiles in collaboration with multiple specialists and institutions, including hospitals and bioinformatics companies from across the nation.

To hear more from these three thought leaders, listen to episode No. 42:

CHOC Radio theme music by Pat Jacobs.

Medical Intelligence and Innovations Institute (MI3) Draws International Interest, Collaboration

Anthony Chang, MD, MBA, MPH, Medical Director, CHOC Children's Heart Institute
Anthony Chang, MD, MBA, MPH, Medical Director, CHOC Children’s Heart Institute

His vision has gone viral in the best possible way. In leading hospital-wide innovation and intelligence at CHOC Children’s, Dr. Anthony Chang, medical director, CHOC Children’s Heart Institute, has galvanized a collaborative, international team of physicians and researchers to transform pediatric medicine.

Representatives from close to 100 pediatric institutions attended last October’s inaugural “Pediatrics 2040” conference of the Sharon Disney Lund Medical Intelligence and Innovations Institute (MI3). An attendee from Bambino Gesù Hospital was so inspired by the conference, he returned to Rome to organize the European version of “Pediatrics 2040” for this fall.

“I never dreamed the meeting could launch a whole new international coalition of pediatric leadership,” said Dr. Chang, who is consulting on the European conference. “It is becoming a universal language to make a difference in pediatrics, and we’re excited that CHOC gets to be a facilitating institution.”

In June, MI3 will sponsor a two-day pediatric innovation leadership forum, the first of its kind among hospital innovation centers, which number fewer than 12. Most of them have confirmed, including Cleveland Clinic, Boston Children’s, Stanford, Children’s at Egleston (Atlanta), Toronto Sick Kids, Children’s Hospital of Michigan and Bambino Gesù Hospital.

Dr. Chang ultimately envisions “innovation engines” in all children’s hospitals. “We inherit good ideas from adult medicine and technology, but why not have innovation start in the children’s hospitals?” he said. “We have every right to expect high-level innovation for children.”

Embracing Technology, Innovation to Improve Care

From nurses to emergency room physicians, MI3 encompasses all CHOC departments and specialties. One possible project is using robotics to enhance patient rounding and parent education. Dr. Chang also has his sights set on the more ambitious goal of creating vast neural networks comprised of the world’s best experts on every pediatric topic.

As healthcare delivery systems and devices become “smarter,” community pediatricians also have a key role, including representation on the MI3 advisory board.

“We have received tremendous support from Michelle Lund and Robert Wilson of the Sharon D. Lund Foundation, and from CHOC, particularly Kim Cripe, Matt Gerlach, Dr. Maria Minon, Dr. Nick Anas, Dr. Jason Knight, Dr. Mustafa Kabeer and Dr. Sharief Taraman,” Dr. Chang said. “CHOC is the first hospital to incorporate intelligence with innovation, and I am grateful for this opportunity.”

Monthly MI3 Meetings

Open to all CHOC medical staff, meetings are held the third Monday of the month and feature updates on genomic medicine, regenerative medicine, nanotechnology, medical devices, artificial intelligence and robotics. For more information, contact Dr. Chang.

MI2: Technological Insights for Your Inner Medical “Geek”

Do emerging technologies such as regenerative medicine, nanotechnology and artificial intelligence ignite your intellectual curiosity? If so, you’ll definitely want to get involved with Medical Intelligence & Innovations Group (MI2), which meets monthly at CHOC Children’s.

This informal venue is open to the CHOC Children’s campus and affiliated medical community members interested in exchanging news, information or ideas concerning emerging medical technology and future trends in medicine. Specific areas of interest include genomic medicine, regenerative medicine, robotic surgery, nanotechnology and artificial intelligence.

Recent presentations and discussions have included:

  • Artifical intelligence and human-computer interface
  • Tissue engineering and “personalized” medicine
  • Wireless tools, tests and apps bringing diagnostic information to the bedside
  • Genome sequencing used to halt the recent MRSA outbreak
  • Biocompatible hydrogels via dynamic optical projection stereolithography (DOPsL)        biofabrications for regenerative medicine
  • Transient/dissolvable electronics • Nanotechnology and glucose-powered fuel cells
  • Nobel-winning work in stem cells, cell signaling and G protein-coupled receptors (GPCRs)
  • Crowdfunding and other National Institute of Health (NIH)-funding alternatives
  • Cyperspace security

Developed by CHOC physicians Anthony Chang, M.D., medical director, CHOC Children’s Heart Institute and Nick Anas, M.D., CHOC Children’s pediatrian-in-chief, MI2 is also studying how new technology is impacting the delivery of pediatric medicine.

 

“A sizable void exists in pediatric medicine in the areas of regenerative medicine, genomic medicine, robotic surgery, artificial intelligence, nanotechnology, biomedical informatics and decision support/outcomes analysis,” Dr. Chang said. “MI2 is an informal venue providing the hospital with a myriad of ideas regarding research and development in these key emerging areas, as well as other emerging technologies.”

MI2 Summer 2013 Internships Available

Three interns were selected for the inaugural MI2 2012 Summer Internship, where they had the opportunity to assist with projects, gain clinical exposure, and present research and topics at the monthly meetings. The first program of its kind in the nation, the MI2 Summer Internship Program is available for high school, undergraduate and graduate students.

 

Anthony Chang, MD MBA MPH

 

Pediatrics 2040: Future Trends and Emerging Innovations in the Next 25 Years

October 3 – 5, 2013

Disneyland Grand Californian Hotel® & Spa, Anahiem

The next 25 years are certain to completely transform medicine. “Pediatrics 2040” is the first meeting of its kind in the nation for physicians, healthcare administrators and other healthcare providers interested the impact of emerging technology and trends on the future delivery of pediatric healthcare.

In addition to the emerging areas – Regenerative Medicine, Genomic Medicine, Robotic Surgery, Artificial Intelligence and Nanotechnology, this comprehensive three-day conference covers:

  • Healthcare policy and finance
  • Innovative research
  • Global health
  • Pediatric epidemiology
  • Healthcare delivery models
  • Social media tools
  • Computer technology

“Pediatrics 2040” is a partnership of CHOC Children’s, the University of California, Irvine, School of Medicine; and the American Academy of Pediatrics.

Curious to learn more? For more information about MI2 monthly meetings, “Pediatrics 2040” or how to support or recommend candidates for the 2013 internship program, please contact Anthony Chang, M.D., at achang@choc.org.